ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ÉúÃü¿ÆÑ§Ñ§Ôº²ÜÓÀ³¤½ÌÊÚÑо¿ÍŶÓÔÚH7N9Á÷¸Ð²¡¶¾¹ãÆ×ÒßÃçÑо¿ÁìÓòÈ¡µÃÍ»ÆÆÐÔÏ£Íû

ÔĶÁÁ¿ £º

¿ËÈÕ£¬ÉúÃü¿ÆÑ§Ñ§ÔºÓк¦ÉúÎï¿ØÖÆÓë×ÊԴʹÓùú¼ÒÖØµãʵÑéÊÒ²ÜÓÀ³¤½ÌÊÚÍŶÓÔÚ¹ú¼Ê¿¹²¡¶¾È¨ÍþÆÚ¿¯¡¶Antiviral Research¡·ÉϽÒÏþÁËÎÊÌâΪ¡°A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice¡±µÄÑо¿ÂÛÎÄ£¬±¨µÀÁËÒ»ÖÖ¶ÔѪÄýËØÂÑ°× £¨Hemagglutinin£¬HA£©¾ÙÐнṹÉè¼ÆµÄH7N9Á÷¸Ð²¡¶¾È«²¡¶¾Ãð»îÒßÃ磬²¢ÇÒ֤ʵÕâÖÖÈ«²¡¶¾Ãð»îÒßÃç¿ÉÒԴ̼¤»úÌ屬·¢H7N9ÑÇÐÍÄÚ¹ãÆ×½»Ö¯ÃâÒß·´Ó³ºÍ½»Ö¯±£»£»¤¡£¡£¡£²ÜÓÀ³¤½ÌÊÚΪ±¾ÎÄͨѶ×÷Õߣ¬²©Ê¿Ñо¿ÉúÍõÑóΪ±¾ÎĵÚÒ»×÷Õß¡£¡£¡£

×Ô2013Äê3ÔÂÎÒ¹úÊ״ᨵÀH7N9Á÷¸Ð²¡¶¾Ñ¬È¾ÈËÒÔÀ´£¬H7N9Á÷¸Ð²¡¶¾ÒѾ­ÂÄÀúÁË5²¨Ê¢ÐУ¬Ñ¬È¾²¡Àý1364Àý£¨×èÖ¹2017Äê4ÔÂ1ÈÕ£©£¬éæÃüÂÊ´ï30%¡£¡£¡£H7N9Á÷¸Ð²¡¶¾²»µ«¾ßÓÐDZÔÚ´óÊ¢ÐеÄÍþв£¬Ò²¶ÔÑøÇÝÒµÔì³ÉÁËÖØ´óµÄËðʧ¡£¡£¡£¸úÆäËûÁ÷¸Ð²¡¶¾Ò»Ñù£¬H7N9Á÷¸Ð²¡¶¾±äÒìÊ®·ÖѸËÙ£¬ÒѾ­ÐγÉÁ˶à¸ö»ùÒòÐÍ£¬Òò´ËÑÐÖÆ¾ßÓйãÆ×½»Ö¯±£»£»¤Ð§¹ûµÄH7N9Á÷¸Ð²¡¶¾ÒßÃçÊ®·ÖÐëÒª¡£¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ÖØ×éH7N9Á÷¸Ð²¡¶¾µÄÕü¾È

²ÜÓÀ³¤½ÌÊÚÍŶÓ֮ǰµÄÑо¿Ö¤ÊµH3ÑÇÐÍHAÂѰ׿çÄ¤Çø£¨Transmembrane domain£¬TM£©ÓëHAÂѰ×ÎȹÌÐÔ¡¢¡¢ ¡¢HAÂѰ׽»Ö¯ÃâÒßÔ­ÐÔ¹ØÏµÇ×½ü£¬Í¨¹ýHA¿çÄ¤ÇøÖû»Õ½ÂÔ¿ÉÒÔÌá¸ßÈý¾Û»¯H1¡¢¡¢ ¡¢H5ºÍH9ÑÇÐÍHAÂѰ׵ÄÑÇÐͼ佻֯±£»£»¤Á¦¡£¡£¡£ÔÚH7N9¹ãÆ×ÒßÃçµÄÑо¿ÖУ¬¸ÃÍŶӽ«H7N9Á÷¸Ð²¡¶¾HAÂѰ×TMÖû»ÎªH3ÑÇÐÍHA TM£¬²¢Í¨¹ý·´ÏòÒÅ´«ÊÖÒÕÕü¾È³ö°üÀ¨TMÖû»µÄÖØ×éH7N9Á÷¸Ð²¡¶¾¡£¡£¡£ÔÚСÊó¶¯ÎïÄ£×ÓÖУ¬ÖØ×鲡¶¾ÖƱ¸µÄÈ«²¡¶¾Ãð»îÒßÃçÄܹ»ÓÕµ¼»úÌ屬·¢Õë¶Ô²î±ð·ÖÖ§¶¾Ö꿹ԭµÄ¸ü¸ßµÄHI¿¹Ìå¡¢¡¢ ¡¢HAÌØÒìÐÔIgG¿¹Ìå¡¢¡¢ ¡¢HAÌØÒìÐÔIFN-¦Ãϸ°ûÒò×Ó¡£¡£¡£¸ÃÒßÃçÄܹ»¶ÔСÊóͬԴ»òÒìÔ´H7N9²¡¶¾¹¥¶¾ÌṩÍêÈ«±£»£»¤£¬¾­ÓÉÃâÒßµÄСÊóÔÚ¹¥¶¾ºó¼ì²â²»µ½·Î²¡¶¾µÎ¶È¡¢¡¢ ¡¢ÎÞÏÔ×ŷβ¿²¡±äºÍÑ×Ö¢·´Ó³¡£¡£¡£

²ÜÓÀ³¤½ÌÊÚÍŶӺã¾Ã¾ÙÐж¯Îﲡ¶¾Ñ§Ñо¿£¬ÏȺó»ñµÃ¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð¡¢¡¢ ¡¢863ÏîÄ¿¡¢¡¢ ¡¢¹ú¼ÒÖØµãÑз¢ÍýÏëÏîÄ¿¡¢¡¢ ¡¢¹ã¶«Ê¡×ÔÈ»¿ÆÑ§»ù½ðµÈ¿ÆÑÐÏîÄ¿µÄ×ÊÖú£¬½ÒÏþSCIÂÛÎÄ30ÓàÆª¡£¡£¡£ÏÖÔÚ¸ÃÍŶÓÖÂÁ¦ÓÚÁ÷¸Ð²¡¶¾·À¿Ø¡¢¡¢ ¡¢¹Ú×´²¡¶¾£¨ÖíÊ¢ÐÐÐÔ¸¹Ðº²¡¶¾PEDV¡¢¡¢ ¡¢¼¦Ñ¬È¾ÐÔÖ§Æø¹ÜÑײ¡¶¾IBV£©ÒÅ´«ÑÝ»¯ºÍÃâÒßÌÓÒÝ»úÖÆÑо¿£¬ÒÑ»ñµÃ¶àÏîÑо¿Ð§¹û¡£¡£¡£

¡¾ÍøÕ¾µØÍ¼¡¿